AtomVie Global Radiopharma
AtomVie Global Radiopharma is a Canadian contract development and manufacturing organization (CDMO) providing cGMP manufacturing and global distribution of radiopharmaceuticals for pharmaceutical and biotechnology companies developing radioligand therapies and radiotherapeutics.
- Company typePrivate
- Founded2022
- HeadquartersHamilton, Canada
- Headcount101–250
- GTM typeB2B
- OfferingServices
What AtomVie Global Radiopharma does
AtomVie Global Radiopharma Inc. is a Canadian contract development and manufacturing organization (CDMO) that provides cGMP manufacturing and global distribution of radiopharmaceuticals for pharmaceutical and biotechnology clients. Spun out of the Centre for Probe Development and Commercialization (CPDC) in August 2022 and headquartered in Hamilton, Ontario, the company carries forward more than a decade of radiopharmaceutical manufacturing expertise, with a workforce of 101–250 including 60+ quality professionals and PhD-level radiochemists. Its service portfolio spans six integrated offerings: process and analytical method development and validation, quality operations (QC/QA/microbiology), regulatory affairs, clinical supply, commercial supply, and global logistics. Manufacturing capabilities cover multi-isotope radiolabeling with Lu-177, Ac-225, I-131, In-111, Zr-89, Tb-161, and Y-90 across ligands ranging from small molecules and peptides to antibodies.
AtomVie's revenue model is contract-based fee-for-service CDMO work, with contracts covering clinical and commercial manufacturing, process development, regulatory submissions, and logistics. The company serves radiopharmaceutical developers across preclinical through Phase III and commercial stages, delivering to 28 countries on six continents with >99% on-time accuracy and turnaround of 72 hours or less. Named enterprise clients include Radiopharm Theranostics, Cellectar Biosciences, POINT Biopharma, and Ariceum Therapeutics. The regulatory team has filed 525+ submissions to Health Canada and the FDA and has cleared 20+ audits by regulators and clients. AtomVie is pre-sellinng clinical and commercial capacity at its new 72,300 sq ft purpose-built facility, scheduled for operational readiness in 2026, which will expand capacity at least 10x over its current footprint. The company is privately held and has raised over $130 million in Series A financing across two tranches led by Avego Management, with co-investors including Genesys Capital and TURNER Group; the Board includes representatives from Avego, Genesys Capital, TURNER Group, and CEO Bruno Paquin.
AtomVie Global Radiopharma firmographics
Firmographics- Name
- AtomVie Global Radiopharma
- Legal name
- AtomVie Global Radiopharma Inc.
- Website
- https://atomvie.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AtomVie Global Radiopharma is a Canadian contract development and manufacturing organization (CDMO) providing cGMP manufacturing and global distribution of radiopharmaceuticals for pharmaceutical and biotechnology companies developing radioligand therapies and radiotherapeutics.
- Ownership category
- akta.pro rank
AtomVie Global Radiopharma industry classification
Industry- Product category
- Radiopharmaceutical CDMO Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
- akta.pro secondary industries
- Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH)
Keywords
Where AtomVie Global Radiopharma is headquartered
LocationHeadquarters
- HQ city
- Hamilton
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
AtomVie Global Radiopharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Supply Chain, Technology or R&D
Revenue model
- Contract Manufacturing Services: AtomVie provides cGMP manufacturing and global distribution of radiopharmaceuticals as a CDMO. Revenue is generated through manufacturing service contracts for clinical and commercial production, including process development, quality operations, regulatory services, and logistics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
AtomVie Global Radiopharma product offering
Product offeringCore offering
AtomVie Global Radiopharma is a Contract Development and Manufacturing Organization (CDMO) providing cGMP manufacturing and global distribution services for radiopharmaceuticals. Its core offerings include process and analytical method development, quality operations, regulatory affairs, clinical supply (Phase I-III), commercial supply, and global logistics, serving pharmaceutical and biotech companies developing radioligand therapies and radiotherapeutics with isotopes such as Lu-177, Ac-225, I-131, In-111, and Zr-89.
Product overview
AtomVie Global Radiopharma Inc. is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive services for radiopharmaceutical manufacturing and global distribution. The company offers an integrated service portfolio comprising six core offerings: Process & Analytical Method Development & Validation (radiolabeling with isotopes including Lu-177, Ac-225, I-131, In-111, Zr-89); Quality Operations (cGMP compliance); Regulatory Affairs (525+ submissions filed); Clinical Supply (4,000+ doses delivered); Commercial Supply (new 72,300 sq ft facility opening 2026); and Logistics (global distribution to 28 countries). These services work together to support clients from Phase 1 clinical development through commercial marketplace launch.
Differentiator
Problem solved
Functional benefit
Products and services
- Process & Analytical Method Development & Validation cGMP radiopharmaceutical manufacturing services including expertise in radiolabeling with radioisotopes such as Lu-177, Ac-225, I-131, In-111, and Zr-89, and ligands ranging from small molecules to peptides and antibodies. Supports early process development, tech transfer, formulation optimization, scale-up, and stability studies for pharmaceutical and biotech clients.
- Quality Operations Quality Control, Quality Assurance, and Microbiology services ensuring compliance with current Good Manufacturing Practices (cGMP) guidelines including Canadian, US, and EU GMP requirements, staffed by 60+ quality professionals.
- Regulatory Services Regulatory affairs support including preparation and filing of submissions to Health Canada and FDA, CMC sections, clinical documents, product monographs, labeling, gap analyses, and pharmacovigilance activities. The team has filed over 525 submissions.
- Clinical Supply Clinical supply services for Phase I to Phase III clinical trials worldwide. Delivered 4,000+ doses since 2023 with >99% accuracy across 28 countries and 6 continents within 72 hours or less.
- Commercial Supply Commercial manufacturing services from the new 72,300 sq ft state-of-the-art facility opening in 2026, with 10x more capacity than current operations. Licensed for Lu-177, Ac-225, I-131, In-111, Tb-161, Y-90 and other isotopes.
- Logistics Global logistics services delivering radiopharmaceuticals to 28 countries across North America, South America, Europe, Asia, Africa, and Australia with just-in-time delivery capabilities and >99% accuracy.
Quantifiable outcome
- >99% accuracy in dose delivery across 28 countries within 72 hours or less
- +3 more outcomes
Companies that use AtomVie Global Radiopharma
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles1 record
AtomVie Global Radiopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AtomVie Global Radiopharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- Ionetix CorporationcoreStrategic supply agreement for GMP-quality Actinium-225 (Ac-225), an alpha-emitting radioisotope, for use in AtomVie's client radiopharmaceutical development and manufacturing programs. This partnership strengthens supply chain reliability and accelerates clinical advancement of targeted alpha therapies.
- TerraPower IsotopescoreStrategic supply agreement for Actinium-225 to advance radiopharmaceutical development and manufacturing, supporting the growth of alpha-based therapies.
- Eckert & ZieglercoreGlobal agreement for Lutetium-177 supply to support AtomVie's radiopharmaceutical manufacturing operations.
- Radiopharm TheranosticscorePartnership to develop and manufacture 177Lu-BetaBart radioantibody for treatment of multiple solid tumors. AtomVie provided GMP manufacturing and distribution services for Phase 1/2a clinical trial.
- RLS (Radiology Linear Services) & UPPIsupportingCollaboration to strengthen existing U.S. radiotherapeutic distribution network for clinical supply.
- McMaster University & TerumosupportingPartnership to manufacture medical devices for cancer treatment in collaboration with McMaster and Terumo.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
AtomVie Global Radiopharma competitors and assessment
Company assessmentDirect peers
- Curium Pharma: Curium is the world's largest pure-play radiopharmaceutical manufacturer, offering contract manufacturing and global distribution of diagnostic and therapeutic radiopharmaceuticals across SPECT, PET, and therapeutic isotopes — directly overlapping AtomVie's CDMO service portfolio and global distribution footprint.
- PETNET Solutions (Siemens Healthineers): PETNET Solutions operates one of the largest PET radiopharma manufacturing and distribution networks globally, serving hospitals and clinical trial sponsors. It is a direct competitor to AtomVie's clinical supply and global logistics services for diagnostic and therapeutic radiopharmaceuticals.
- Cardinal Health Nuclear & Precision Health: Cardinal Health distributes radiopharmaceuticals to U.S. hospitals and operates manufacturing and radiopharmacy services — directly comparable to AtomVie's North American clinical/commercial supply and global logistics offerings for therapeutic radiopharmaceuticals.
- Eckert & Ziegler: Eckert & Ziegler is both a Lu-177 supplier to AtomVie and an independent radiopharma CDMO via its Medical segment. It directly competes for radiopharmaceutical contract manufacturing business while also serving as an ecosystem partner.
Emerging players
- SpectronRx: SpectronRx is an emerging U.S.-based CDMO providing radiopharmaceutical contract development, manufacturing, and distribution including alpha and beta emitters — directly competing with AtomVie for biotech CDMO clients, particularly in the alpha-therapy space.
- Nucleus RadioPharma: Nucleus RadioPharma is a purpose-built radiopharma CDMO developing a nationwide network of manufacturing facilities for therapeutic radiopharmaceuticals. It competes with AtomVie for emerging biotech outsourcing relationships and capital.
- NorthStar Medical Radioisotopes: NorthStar is a U.S.-based radioisotope production company focused on Mo-99/Tc-99m and emerging therapeutic isotopes. It competes with AtomVie in the broader radiopharma supply chain, particularly for therapeutic isotope production capacity.
Broad incumbents
- Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with in-house manufacturing and a portfolio including PNT2002/PSMA assets. While it primarily develops its own products rather than serving as a CDMO, it overlaps AtomVie's radiopharmaceutical manufacturing capabilities and competes for talent and isotope supply.
- GE HealthCare (Pharmaceutical Diagnostics / Radiopharma): GE HealthCare operates a global PET radiotracer production network through its Pharmaceutical Diagnostics segment. It is a broad incumbent that overlaps AtomVie's radiopharma manufacturing and distribution, though from a much larger scale and broader portfolio base.
- IBA (Ion Beam Applications): IBA is a major player in radioisotope production and radiopharma solutions, including PET isotope supply and emerging therapeutic isotope capabilities. It overlaps AtomVie's upstream isotope production and downstream manufacturing exposure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
AtomVie Global Radiopharma social profiles
Digital presenceAtomVie Global Radiopharma compliance and trust
Trust signalCompliance2 records
AtomVie Global Radiopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
AtomVie Global Radiopharma leadership team
Management profileNumber of profiles
Profiles10 records
AtomVie Global Radiopharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AtomVie Global Radiopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AtomVie Global Radiopharma
What does AtomVie Global Radiopharma do?
AtomVie Global Radiopharma is a Contract Development and Manufacturing Organization (CDMO) providing cGMP manufacturing and global distribution services for radiopharmaceuticals. Its core offerings include process and analytical method development, quality operations, regulatory affairs, clinical supply (Phase I-III), commercial supply, and global logistics, serving pharmaceutical and biotech companies developing radioligand therapies and radiotherapeutics with isotopes such as Lu-177, Ac-225, I-131, In-111, and Zr-89.
Is AtomVie Global Radiopharma a public or private company?
AtomVie Global Radiopharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was AtomVie Global Radiopharma founded?
AtomVie Global Radiopharma was founded in 2022. It employs 101 to 250 people.
Where is AtomVie Global Radiopharma based?
AtomVie Global Radiopharma is headquartered in Hamilton, Canada, in the North America region.
How does AtomVie Global Radiopharma make money?
One revenue line is on record: contract Manufacturing Services.
Who are AtomVie Global Radiopharma's main competitors?
Direct peers on record are Curium Pharma, PETNET Solutions (Siemens Healthineers), Cardinal Health Nuclear & Precision Health and Eckert & Ziegler. Emerging players are SpectronRx, Nucleus RadioPharma and NorthStar Medical Radioisotopes. Broad incumbents are Lantheus Holdings, GE HealthCare (Pharmaceutical Diagnostics / Radiopharma) and IBA (Ion Beam Applications).
Does AtomVie Global Radiopharma have an API?
No public API is recorded for AtomVie Global Radiopharma.
What industry is AtomVie Global Radiopharma in?
AtomVie Global Radiopharma's product category is Radiopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 3254 and its SIC code is 5122.